Zoi Tsourti

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Rafał Dziadziuszko, Egbert F. Smit, Urania Dafni et al. · Journal of Thoracic Oncology · 2019 · 155 citations · Full text

Medicine, Oncology, Pharmacology +17

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

Solange Peters, Enriqueta Felip, Urania Dafni et al. · Journal of Thoracic Oncology · 2020 · 136 citations · Full text

Medicine, Oncology, Chemotherapy +15

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

M. Pérol, Enriqueta Felip, Urania Dafni et al. · Annals of Oncology · 2022 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

Igor Letovanec, Stephen P. Finn, Panagiota Zygoura et al. · Journal of Thoracic Oncology · 2017 · 84 citations · Full text

Medicine, Cancer Biology, Oncology +7